The Biden administration on Tuesday (August 29) released its list of 10 prescription medicines that will be subject to the first-ever price negotiations by the U.S. Medicare health program that covers 66 million people, with big-selling blood thinner Eliquis from Bristol Myers Squibb and Pfizer among them.
U.S President Joe Biden said in a statement that once implemented, the prices of negotiated drugs will decrease for up to 9 million seniors who currently pay as much as $6,497 in out-of-pocket costs per year for these prescriptions.
Medicines on the list include Merck & Co’s diabetes drug Januvia, Eliquis rival Xarelto from Johnson & Johnson, and AbbVie’s leukemia treatment Imbruvica.
Other drugs on the list include Amgen’s rheumatoid arthritis drug Enbrel, Boehringer Ingelheim, Eli Lilly’s diabetes drug Jardiance, J&J’s arthritis and Crohn’s disease Stelara, and insulin from Novo Nordisk.
#medicare #whitehouse
The New York Post is your source for breaking news, news about New York, sports, business, entertainment, opinion, real estate, culture, fashion, and more.
Subscribe to New York Post Sports: https://www.youtube.com/c/nypostsports
Catch the latest news here: https://nypost.com/
Follow The New York Post on:
Twitter – https://twitter.com/nypost
Facebook – https://www.facebook.com/NYPost